1. An isolated human antibody or antigen binding fragment thereof that specifically binds a human delta-like ligand 4 (hDll4) for use in treating cancer or slowing or stopping tumor growth in a subject by administration in combination with a chemotherapeutic agent, wherein the human antibody or antigen binding thereof the fragment contains the variable region of the heavy chain (HCVR) containing the sequences CDR1, CDR2 and CDR3 of the heavy chain of SEQ ID Nos. 22, 24 and 26, respectively, and the variable region of the light chain (LCVR) containing the last CDR1, CDR2, and CDR3 light chain sequences of SEQ ID Nos. 30, 32, and 34, respectively. 2. The human antibody or antigen binding fragment according to claim 1, wherein the antibody or antigen binding fragment comprises the HCVR sequence of SEQ ID No. 20 or SEQ ID No. 116 or the LCVR sequence of SEQ ID No. 28 or SEQ ID No. 118.3. The human antibody or antigen binding fragment of claim 1, wherein said antibody or antigen binding fragment comprises a combination of HCVR / LCVR SEQ ID No. 20/28 or 116 / 118.4. A human antibody or antigen binding fragment according to any one of the preceding paragraphs, wherein the chemotherapeutic agent is at least one selected from the group consisting of an antimitotic agent, a platinum-based chemotherapeutic agent, a receptor tyrosine kinase inhibitor, a pyrimidine analog, a topoisomerase inhibitor, and an adjuvant. 5. The human antibody or antigen binding fragment according to claim 4, wherein the antimitotic agent is docetaxel or paclitaxel； or a pharmaceutically acceptable analogue thereof or a salt thereof. 6. The human antibody or antigen binding fragment according to claim 4, wherein the chemotherapeutic agent is based on a plate�1. Выделенное антитело человека или его антигенсвязывающий фрагмент, которые специфически связывают дельта-подобный лиганд 4 человека (hDll4), для применения при лечении рака или замедлении или остановке роста опухоли у субъекта посредством введе
